Intensity Therapeutics 8-K: Officer/Director Changes, Comp Arrangements
Ticker: INTS · Form: 8-K · Filed: Feb 7, 2024 · CIK: 1567264
| Field | Detail |
|---|---|
| Company | Intensity Therapeutics, Inc. (INTS) |
| Form Type | 8-K |
| Filed Date | Feb 7, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: executive-changes, compensation, governance
TL;DR
**Intensity Therapeutics filed an 8-K about executive changes and pay, keep an eye on leadership shifts.**
AI Summary
Intensity Therapeutics, Inc. filed an 8-K on February 7, 2024, reporting events that occurred on February 6, 2024. This filing primarily concerns changes in director or officer compensation arrangements, as well as potential departures or elections of directors or officers. For investors, this matters because changes in executive compensation or leadership can signal shifts in company strategy, financial health, or governance, potentially impacting future stock performance.
Why It Matters
Changes in executive compensation or leadership can influence a company's strategic direction and operational efficiency, directly affecting investor confidence and stock valuation.
Risk Assessment
Risk Level: medium — Changes in executive compensation and leadership can introduce uncertainty, but the specific details are not fully disclosed in this summary, making the impact moderate.
Analyst Insight
An investor should monitor subsequent filings or company announcements for specific details regarding the changes in directors, officers, or compensatory arrangements, as this 8-K only signals that such events have occurred without providing specifics.
Key Players & Entities
- Intensity Therapeutics, Inc. (company) — the registrant filing the 8-K
- February 6, 2024 (date) — date of the earliest event reported
- February 7, 2024 (date) — date the 8-K was filed
- 001-41109 (other) — Commission File Number
- Delaware (other) — State of Incorporation
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 6, 2024.
What specific items are covered in this 8-K filing according to the 'ITEM INFORMATION' section?
The 8-K filing covers 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' and 'Financial Statements and Exhibits'.
What is the full legal name of the company that filed this 8-K?
The exact name of the registrant as specified in its charter is Intensity Therapeutics, Inc.
What is the Commission File Number for Intensity Therapeutics, Inc.?
The Commission File Number for Intensity Therapeutics, Inc. is 001-41109.
Where is Intensity Therapeutics, Inc.'s principal executive office located?
The principal executive office of Intensity Therapeutics, Inc. is located at 1 Enterprise Drive, Suite 430, Shelton, CT 06484-4779.
Filing Stats: 659 words · 3 min read · ~2 pages · Grade level 12.5 · Accepted 2024-02-07 16:15:27
Key Financial Figures
- $0.0001 — ge on Which Registered: Common Stock, $0.0001 par value per share INTS The NASDAQ
Filing Documents
- ea193020-8k_intensity.htm (8-K) — 29KB
- ea193020ex10-1_intensity.htm (EX-10.1) — 41KB
- ex10-1_001.jpg (GRAPHIC) — 2KB
- 0001213900-24-011098.txt ( ) — 252KB
- ints-20240206.xsd (EX-101.SCH) — 3KB
- ints-20240206_lab.xml (EX-101.LAB) — 33KB
- ints-20240206_pre.xml (EX-101.PRE) — 22KB
- ea193020-8k_intensity_htm.xml (XML) — 4KB
02
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 6, 2024, the board of directors (the "Board") of Intensity Therapeutics, Inc. (the "Company"), upon the recommendation of the Compensation Committee of the Board, approved and adopted the Incentive Compensation Plan (the "Plan"). The purpose of the Plan is to incentivize participants to achieve Individual Performance Objectives/Key Results and contribute to Company Milestones, collectively yielding effective Company Performance. The Plan is retroactively effective as of October 1, 2023. Pursuant to the Plan, all salaried employees of the Company, including its executive officers, will be eligible to receive cash compensation based on attainment of certain performance goals ("Performance Goals") tied to both individual performance, and performance of the Company as a whole. The Performance Goals will be set annually and will be pre-established by the Company's Chief Executive Officer and will be approved by the Company's Board. If the Performance Goals are achieved, a Plan participant's bonus will be calculated with a formula that takes a percentage of the participant's salary and multiplies that by weighted percentages that correspond to the achievement of the individual Performance Goals and the Company Performance Goals. The aforementioned weighted percentages will vary based on the Plan Participant's level of impact on overall Company performance. The foregoing summary of the Plan does not purport to be complete and is qualified in its entirety by reference to the full text of the Plan, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits ExhibitNo. Description of Document 10.1 Incentive Compensation Plan 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 7, 2024 Intensity Therapeutics, Inc. By: /s/ Lewis H. Bender Name: Lewis H. Bender Title: Chief Executive Officer [ Signature Page to the Form 8-K ] 2